Johnson & Johnson Settles 3rd Risperdal Lawsuit for $158M
If companies are people, my friend, like Mitt Romney famously described in Iowa in August 2011, then we’re feeling a little bad for our fellow person called Janssen Pharmaceuticals, a division of health care giant Johnson & Johnson.
They just got dinged with a $158 million settlement in a Medicaid fraud case in Texas for “making false or misleading statements about the safety, cost and effectiveness of the expensive anti-psychotic medication Risperdal, and improperly influencing officials and doctors to push the drug.”
But we won’t feel too badly, because Janssen got off easy with this one. They don’t have to admit to any liability with the settlement, and Johnson & Johnson — who made billions off of the sale of Risperdal — will barely blink their corporate eyeballs as they make out the check.


Dear Mrs. ——–
People with Alzheimer’s disease often suffer not only from the debilitating effects of the disease itself, but also from the secondary psychological effects. Delusions and hallucinations appear in up to 50 percent of those with Alzheimer’s, and as many as 70 percent demonstrate aggressive behaviors and agitation. Both caregivers and family members are distressed by these symptoms, and so everyone is motivated to treat the person with Alzheimer’s with antipsychotic medications.
Last week, I had the opportunity to report from
I remain astounded that psychiatrists and pediatricians think it’s occasionally appropriate to prescribe adult atypical antipsychotic medications — like Risperdal — to children younger than age 5.
You’ve been diagnosed with a mental disorder and have been in treatment now for years. You’ve done both psychotherapy and psychiatric medications, and now it’s time to try to live life drug-free. You’ve
A while back, a reader asked me if I’d cover the topic of intimacy complications with regard to antidepressants.
Schizophrenia is one of those mental disorders that many people seem to confuse with …
Awhile back, a
Bipolar disorder has been the focus of attention in …